Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Current Assets (2022 - 2025)

Historic Current Assets for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $8.6 million.

  • bioAffinity Technologies' Current Assets rose 23790.27% to $8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year increase of 23790.27%. This contributed to the annual value of $2.7 million for FY2024, which is 3216.03% down from last year.
  • As of Q3 2025, bioAffinity Technologies' Current Assets stood at $8.6 million, which was up 23790.27% from $1.7 million recorded in Q2 2025.
  • bioAffinity Technologies' 5-year Current Assets high stood at $14.1 million for Q3 2022, and its period low was $1.7 million during Q2 2025.
  • Moreover, its 4-year median value for Current Assets was $4.0 million (2023), whereas its average is $6.1 million.
  • Its Current Assets has fluctuated over the past 5 years, first crashed by 6904.53% in 2024, then soared by 23790.27% in 2025.
  • Quarter analysis of 4 years shows bioAffinity Technologies' Current Assets stood at $12.0 million in 2022, then crashed by 66.79% to $4.0 million in 2023, then tumbled by 32.16% to $2.7 million in 2024, then soared by 219.6% to $8.6 million in 2025.
  • Its last three reported values are $8.6 million in Q3 2025, $1.7 million for Q2 2025, and $1.9 million during Q1 2025.